商品名：Diabeta, Micronase, Glynase, and Glibenclamide
Glyburide is a sulfonylurea oral hypoglycemic agent; it is also known as glibenclamide. This drug acts to increase secretion of insulin from pancreas, probably by interacting with sulfonylurea receptors on beta cells or by interfering with adenosine triphosphate (ATP)–sensitive potassium channels on pancreatic beta cells, which increases secretion of insulin. These drugs also may increase sensitivity of existing insulin receptors. It is used as oral treatment in the management of diabetes mellitus, particularly in cats. The response rate is approximately 40%. Sulfonylurea drugs include glipizide (Glucotrol) and glyburide (DiaBeta, Micronase). Metformin is of the biguanide class of oral drugs for diabetes.
Oral hypoglycemic agents are successful in people only for noninsulin-dependent diabetes. There has been only limited use in animals. Glyburide is not effective in dogs but has been used in some cats. Some cats may initially respond to oral hypoglycemic agents but eventually need insulin treatment. Similar drugs include acetohexamide, chlorpropamide, glipizide, gliclazide, and tolazamide. There is more Glyburide 345 G experience with glipizide than with other drugs, and it should be used as the first choice (see Glipizide section for more details.).
劑量數字暫停提供：VetPro 的劑量改依 DRUGAPI 藥物資料庫對外的內容，DRUGAPI 目前不提供可直接計算的劑量。下方列出 DRUGAPI 的審查結論與劑量審查引用的來源；計算機可手動輸入劑量換算。
公開資料包含人用標籤、次級獸醫參考、單一貓病例與小型毒物暴露系列，但缺少精確成品、族群、劑量、監測、療效與安全性的完整獸醫契約；所有 runtime 必須封閉。
依出現頻率分組；嚴重副作用獨立列出，臨床上需立即辨識。